BBC vs CANC

Virtus Biotech Clinical Trials ETF against Tema Oncology ETF: cost, size, returns, what they hold and how much of it is the same.

Overlap by weight
19%
26 shared positions
Fee gap
10 bp
BBC is cheaper
1-year return gap
16.1 pts
BBC is ahead
Larger fund
CANC
$203M

Side by side

BBCCANC
FundVirtus Biotech Clinical Trials ETFTema Oncology ETF
IssuerVirtusTema
CategoryBiotech & Health InnovationBiotech & Health Innovation
Expense ratio0.65%0.75%
Assets$42M$203M
Average daily dollar volume$866K$1.3M
ListedDec 16, 2014Aug 14, 2023
FrenzyCap score4436
1-month return−11.6%−2.4%
3-month return−14.0%−0.4%
Year to date+14.5%+17.5%
1-year return+52.3%+36.2%
30-day volatility32.2%21.4%
Worst drawdown, 1 year−22.8%−11.3%
Trailing 12-month yield1.49%0.05%
Holdings12557
Top 10 weight16.2%42.9%
Look-through P/E——
Holdings vs fair value+16.7%+5.0%
Holdings above 200-day average46%61%
Net flow, latest 3 reported months+$5.1M thru Jul 2026+$14M thru May 2026
30-day implied volatility43.3%—
Holdings as ofas of Apr 30, 2026SEC filingas of May 31, 2026SEC filing

Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.

Largest shared holdings

25% of BBC · 43% of CANC
HoldingBBCCANC
RVMD1.35%7.73%
ELVN1.81%1.31%
CGON1.21%2.43%
RLAY1.19%1.28%
ERAS2.19%1.08%
ANAB1.08%0.99%
SMMT0.90%1.21%
RCUS0.88%1.20%
IMNM0.87%3.91%
CELC0.85%3.58%
IMMATICS NV0.81%1.12%
ZYME0.80%1.51%
CRVS1.34%0.76%
AVBP0.94%0.73%
NUVL0.71%3.37%
IDYA0.63%2.27%
COGT0.63%4.10%
INBX1.20%0.60%
CGEM0.81%0.59%
CTMX0.74%0.47%
ARVN0.58%0.43%
JANX0.69%0.43%
TRAX0.38%0.53%
OLMA0.32%0.60%
TYRA1.14%0.30%

Sector mix of the stock holdings

SectorBBCCANCGap
Health Care92.6%84.5%+8.1%
Technology0.6%0.0%+0.6%

More: full overlap table · BBC holdings · CANC holdings

Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.